NanoPhoria

📍 Milan, Italy🗓 Founded 2022👥 10 employees💰 Last funded Aug 2025
Biotechnology🌐 nanophoria.com
Website LinkedIn
NanoPhoria is a preclinical stage biotech company pioneering inhalable cardiovascular treatments via non-viral nano-delivery of biologics. The Company is devoted to the clinical development of an innovative proprietary platform for the tissue-directed delivery of therapeutic peptides and RNAs. The core vehicle is an inorganic calcium-phosphate nanoparticle which represents a versatile, biomimetic nano-carrier that can be loaded or surface decorated with biologics and can be formulated for inhalation or for other administration routes. NanoPhoria’s lead product, NP-MP1 is an inhalable nano-in-micro formulation, delivering a proprietary peptide, first-in-class calcium channel modulator, for the treatment of Heart Failure with reduced Ejection Fraction, a chronic syndrome affecting the lives of millions worldwide.
2
Total investors
0
Early stage
2
Mid stage
0
Late stage
2022
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United Kingdom
1
Italy
1
Frequently asked questions
Who invested in NanoPhoria?
NanoPhoria has 2 investors on record on gritt.io, 2 mid-stage.
When did NanoPhoria last raise funding?
The most recent investment in NanoPhoria recorded on gritt.io was in August 2025.
When was NanoPhoria founded?
NanoPhoria was founded in 2022.
What industry is NanoPhoria in?
NanoPhoria operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is NanoPhoria based?
NanoPhoria is headquartered in Milan, Italy.